Seeking Alpha

Pfizer's Xalkori lung-cancer drug performs well in another Phase III

  • Pfizer's (PFE) Xalkori (Crizotinib) treatment met the main goal of a Phase III trial of untreated patients with a certain form of lung cancer by "significantly prolonging progression-free survival (PFS)" when compared with standard chemotherapy.
  • The study, called Profile 1014, is the second positive global Phase III test that evaluated Xalkori against chemotherapy.
  • Xalkori has already been authorized to treat previously treated patients. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs